{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-091099","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2026-08-05T20:11:23+00:00","discovered_at":"2026-08-05T20:13:11.681137+00:00","generated_at":"2026-08-05T20:13:45.396152+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Protagonist Q2 net income $162.8M; ICOTYDE launch, rusfertide PDUFA in Aug 2026","bullets":["Q2 2026 net income $162.8M ($2.47 basic EPS) vs net loss $34.8M in Q2 2025; revenue $213.5M from Takeda opt-out and J&J milestones.","ICOTYDE (icotrokinra) first full quarter of commercial sales; FDA approved Mar 2026; J&J partnership with up to $580M milestones and 6-10% royalties.","Rusfertide NDA under priority review for polycythemia vera; PDUFA date Aug 2026; Takeda opt-out triggered $200M payment, additional $200M and $75M upon approval.","PN-881 (oral IL-17 antagonist) Phase 2b psoriasis program planned early Q1 2027; PN-477sc (triple agonist) Phase 1 initiated.","Cash $849.5M as of June 30, 2026; potential share buyback program announcement by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-091099","json":"https://secwatch.observer/filing/0001104659-26-091099.json","markdown":"https://secwatch.observer/filing/0001104659-26-091099.md","text":"https://secwatch.observer/filing/0001104659-26-091099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/0001104659-26-091099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:13:45.396152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}